Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (Nasdaq: TSHA) announced that its Compensation Committee has granted a stock option to one new employee on January 2, 2025. The grant includes options to purchase 311,000 shares of common stock at an exercise price of $1.85 per share, matching the closing price on the grant date. The stock option was issued under the company's 2023 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The option has a 10-year term and follows a four-year vesting schedule: 25% vests after the first year, with the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.
Taysha Gene Therapies (Nasdaq: TSHA) ha annunciato che il suo Comitato Compensi ha concesso un'opzione su azioni a un nuovo dipendente il 2 gennaio 2025. L'assegnazione include opzioni per l'acquisto di 311.000 azioni di azioni ordinarie a un prezzo di esercizio di $1,85 per azione, corrispondente al prezzo di chiusura alla data di concessione. L'opzione su azioni è stata emessa ai sensi del Piano di Inducimento 2023 dell'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). L'opzione ha un termine di 10 anni e segue un programma di maturazione di quattro anni: il 25% matura dopo il primo anno, con il restante 75% che matura mensilmente nei successivi 36 mesi, a condizione di continuare l'impiego.
Taysha Gene Therapies (Nasdaq: TSHA) anunció que su Comité de Compensación ha otorgado una opción de compra de acciones a un nuevo empleado el 2 de enero de 2025. La concesión incluye opciones para comprar 311,000 acciones ordinarias a un precio de ejercicio de $1.85 por acción, coincidiendo con el precio de cierre en la fecha de la concesión. La opción fue emitida bajo el Plan de Inducción 2023 de la compañía, cumpliendo con la Regla de Cotización 5635(c)(4) de Nasdaq. La opción tiene un término de 10 años y sigue un calendario de adquisición de cuatro años: el 25% se adquiere después del primer año, y el 75% restante se adquiere mensualmente durante los siguientes 36 meses, condicionado a la continuidad del empleo.
Taysha Gene Therapies (Nasdaq: TSHA)는 2025년 1월 2일 신규 직원에게 스톡 옵션을 부여했다고 발표했습니다. 이 부여에는 311,000 주의 보통주를 주당 $1.85의 행사가로 구매할 수 있는 옵션이 포함되어 있으며, 이는 부여일의 마감가와 일치합니다. 이 스톡 옵션은 회사의 2023 유인 계획에 따라 발급되었으며, Nasdaq 상장 규정 5635(c)(4)를 준수합니다. 이 옵션은 10년 기간을 가지며 4년 분할 일정에 따라 진행됩니다: 1년 후에 25%가 가득 차고, 나머지 75%는 다음 36개월 동안 매월 가득 차며, 재직 조건에 따라 다릅니다.
Taysha Gene Therapies (Nasdaq: TSHA) a annoncé que son Comité de Rémunération a accordé une option sur actions à un nouvel employé le 2 janvier 2025. L'attribution comprend des options permettant d'acheter 311 000 actions ordinaires à un prix d'exercice de $1,85 par action, en correspondance avec le prix de clôture à la date de l'attribution. L'option sur actions a été émise dans le cadre du Plan d'Incitation 2023 de l'entreprise, conformément à la Règle d'Inscription Nasdaq 5635(c)(4). L'option a une durée de 10 ans et suit un calendrier de maturation de quatre ans : 25 % mûrissent après la première année, les 75 % restants mûrissent mensuellement au cours des 36 mois suivants, sous réserve de maintien de l'emploi.
Taysha Gene Therapies (Nasdaq: TSHA) gab bekannt, dass der Vergütungsausschuss einem neuen Mitarbeiter am 2. Januar 2025 eine Aktienoption gewährt hat. Die Gewährung umfasst Optionen zum Kauf von 311.000 Aktien zum Ausübungspreis von $1,85 pro Aktie, was dem Schlusskurs am Tag der Gewährung entspricht. Die Aktienoption wurde im Rahmen des Unternehmensplans zur Anwerbung von 2023 ausgestellt und entspricht der Nasdaq-Listing-Regel 5635(c)(4). Die Option hat eine Laufzeit von 10 Jahren und folgt einem vierjährigen Vesting-Zeitplan: 25% werden nach dem ersten Jahr fällig, die verbleibenden 75% werden in den folgenden 36 Monaten monatlich fällig, abhängig von der fortgesetzten Beschäftigung.
- New employee compensation aligned with market value through equity-based incentives
- Long-term retention strategy implemented through 4-year vesting schedule
- Potential dilution of existing shareholders through new stock option issuance
DALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on January 2, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 311,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
What is the exercise price of TSHA's new stock option grant announced on January 2, 2025?
How many shares were included in TSHA's January 2025 inducement grant?
What is the vesting schedule for TSHA's January 2025 stock option grant?
Under which plan was TSHA's January 2025 stock option grant issued?
